<p>根据 Neuberger Berman Group LLC 最近向证券交易委员会提交的文件，该公司在第二季度减少了对 AbbVie Inc.（纽约证券交易所代码：ABBV - 免费报告）的持股比例，降幅为 9.7%。该机构投资者在此期间出售了 132,804 股后，持有 1,240,254 股该公司的股票。到最近一个季度末，Neuberger Berman Group LLC 持有的 AbbVie 股份占比为 0.07%，价值为 2.30216 亿美元。</p>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p>其他大型投资者最近也买卖了该公司的股票。Conning Inc.在第二季度将其在 AbbVie 的持股增加了 7.1%。Conning Inc.现在拥有 191,023 股该公司的股票，价值为 3,545.8 万美元，此前在上个季度又购买了 12,690 股。Dohj LLC 在第二季度将其在 AbbVie 的持股提高了 41.8%。Dohj LLC 现在拥有 4,529 股该公司的股票，价值为 80.2 万美元，此前在此期间又购买了 1,335 股。First Hawaiian Bank 在第二季度将其在 AbbVie 的持股提高了 0.8%。First Hawaiian Bank 现在拥有 7,556 股该公司的股票，价值为 140.3 万美元，此前在上个季度又购买了 60 股。BankPlus Trust Department 在第二季度将其在 AbbVie 的持股提高了 3.3%。BankPlus Trust Department 现在拥有 27,113 股该公司的股票，价值为 503.3 万美元，此前在此期间又购买了 855 股。最后，Whittier Trust Co.在第二季度将其在 AbbVie 的持股增加了 4.0%。Whittier Trust Co.现在拥有 237,030 股该公司的股票，价值为 4,399.7 万美元，此前在上个季度又购买了 9,073 股。机构投资者和对冲基金持有该公司 70.23% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>多位分析师对该股票发表了评论。瑞银集团在 11 月 7 日的研究报告中将 AbbVie 的目标价格从 195.00 美元上调至 220.00 美元，并给予该公司 “中性” 评级。斯科舍银行在 11 月 13 日的报告中开始覆盖 AbbVie 的股票。他们对该股票设定了 “行业表现优于大盘” 的评级和 280.00 美元的目标价格。汇丰全球研究在 10 月 1 日的研究报告中将 AbbVie 的评级从 “强力买入” 下调至 “持有”。派珀桑德勒在 11 月 5 日的研究报告中重申了 “增持” 评级，并将 AbbVie 的目标价格设定为 289.00 美元（上调自 284.00 美元）。最后，美国银行在 10 月 3 日的报告中将 AbbVie 的目标价格从 220.00 美元上调至 251.00 美元，并给予该公司 “中性” 评级。两位投资分析师对该股票给予 “强力买入” 评级，十三位给予 “买入” 评级，十位给予 “持有” 评级。根据 MarketBeat 的数据，AbbVie 的平均评级为 “适度买入”，共识目标价格为 241.85 美元。</p>
<ul>
<li>医疗保健轮动正在进行中：3 只领先股票</li>
</ul>
<p><strong>查看我们最新的 ABBV 股票报告</strong></p>
<h2>AbbVie 股价下跌 1.8%</h2>
<p>纽约证券交易所代码：ABBV 的股票在周五以 227.57 美元开盘。AbbVie Inc.的 12 个月低点为 164.39 美元，12 个月高点为 244.81 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务与股本比率为 44.14。该公司的市值为 4022 亿美元，市盈率为 108.37，市盈增长比率为 1.42，贝塔值为 0.50。该公司的 50 日移动平均线为 227.62 美元，200 日移动平均线为 206.42 美元。</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底线</li>
</ul>
<p>AbbVie（纽约证券交易所代码：ABBV - 获取免费报告）最近在 10 月 31 日发布了季度盈利数据。该公司报告每股收益（EPS）为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。AbbVie 的股本回报率为 699.66%，净利润率为 6.45%。该公司在本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。去年同期，该公司的每股收益为 3.00 美元。该公司的季度收入同比增长 9.1%。AbbVie 已将其 2025 年第四季度的指导目标设定为 3.320-3.360 EPS。平均而言，股票分析师预计 AbbVie Inc.在当前财年将发布 12.31 EPS。</p>
<h2>AbbVie 增加股息</h2>
<p>该公司最近还披露了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）登记的投资者将获得每股 1.73 美元的股息。该股息的除息日期为 1 月 16 日（星期五）。这比 AbbVie 之前的季度股息 1.64 美元有所增加。这代表着每年 6.92 美元的股息，收益率为 3.0%。AbbVie 的派息比率为 524.24%。</p>
<h2>关于 AbbVie</h2>
<p>（免费报告）</p>
<p>AbbVie Inc.在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道 Behçet 病以及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块状银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 AbbVie</li>
<li>基础材料股票投资</li>
<li>3 只适合投资 AI 基础设施演变的股票</li>
<li>投资建筑股票</li>
<li>Semtech 的数据中心芯片如何推动 AI 热潮</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Keysight Technologies 的激增：市场意识到这一 AI 投资机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Neuberger Berman Group LLC 在第二季度减少了对艾伯维的持股，减幅为 9.7%，目前持有 1,240,254 股，价值 2.302 亿美元。其他投资者也调整了他们的持股，其中一些增加了他们的股份。分析师对艾伯维的评级不一，普遍目标价为 241.85 美元。艾伯维报告了第三季度每股收益为 1.86 美元，超出预期，并增加了股息。该股票开盘价为 227.57 美元，市值为 4022 亿美元</p>

<p>Neuberger Berman Group LLC lessened its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 9.7% in the second quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 1,240,254 shares of the company's stock after selling 132,804 shares during the period. Neuberger Berman Group LLC owned 0.07% of AbbVie worth $230,216,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Neuberger Berman Group LLC 最近向证券交易委员会提交的文件，该公司在第二季度减少了对 AbbVie Inc.（纽约证券交易所代码：ABBV - 免费报告）的持股比例，降幅为 9.7%。该机构投资者在此期间出售了 132,804 股后，持有 1,240,254 股该公司的股票。到最近一个季度末，Neuberger Berman Group LLC 持有的 AbbVie 股份占比为 0.07%，价值为 2.30216 亿美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Conning Inc. increased its holdings in shares of AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company's stock valued at $35,458,000 after buying an additional 12,690 shares in the last quarter. Dohj LLC raised its position in shares of AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company's stock worth $802,000 after purchasing an additional 1,335 shares during the period. First Hawaiian Bank lifted its holdings in shares of AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock valued at $1,403,000 after purchasing an additional 60 shares during the last quarter. BankPlus Trust Department boosted its position in shares of AbbVie by 3.3% in the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company's stock valued at $5,033,000 after purchasing an additional 855 shares during the period. Finally, Whittier Trust Co. increased its stake in AbbVie by 4.0% in the 2nd quarter. Whittier Trust Co. now owns 237,030 shares of the company's stock worth $43,997,000 after purchasing an additional 9,073 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也买卖了该公司的股票。Conning Inc.在第二季度将其在 AbbVie 的持股增加了 7.1%。Conning Inc.现在拥有 191,023 股该公司的股票，价值为 3,545.8 万美元，此前在上个季度又购买了 12,690 股。Dohj LLC 在第二季度将其在 AbbVie 的持股提高了 41.8%。Dohj LLC 现在拥有 4,529 股该公司的股票，价值为 80.2 万美元，此前在此期间又购买了 1,335 股。First Hawaiian Bank 在第二季度将其在 AbbVie 的持股提高了 0.8%。First Hawaiian Bank 现在拥有 7,556 股该公司的股票，价值为 140.3 万美元，此前在上个季度又购买了 60 股。BankPlus Trust Department 在第二季度将其在 AbbVie 的持股提高了 3.3%。BankPlus Trust Department 现在拥有 27,113 股该公司的股票，价值为 503.3 万美元，此前在此期间又购买了 855 股。最后，Whittier Trust Co.在第二季度将其在 AbbVie 的持股增加了 4.0%。Whittier Trust Co.现在拥有 237,030 股该公司的股票，价值为 4,399.7 万美元，此前在上个季度又购买了 9,073 股。机构投资者和对冲基金持有该公司 70.23% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of analysts have commented on the stock. UBS Group upped their price objective on shares of AbbVie from $195.00 to $220.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, November 7th. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $280.00 price target on the stock. Hsbc Global Res lowered shares of AbbVie from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, October 1st. Piper Sandler reissued an &#34;overweight&#34; rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Finally, Bank of America increased their target price on AbbVie from $220.00 to $251.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, AbbVie has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $241.85.</p>
<div class="lb-trans"><p>多位分析师对该股票发表了评论。瑞银集团在 11 月 7 日的研究报告中将 AbbVie 的目标价格从 195.00 美元上调至 220.00 美元，并给予该公司 “中性” 评级。斯科舍银行在 11 月 13 日的报告中开始覆盖 AbbVie 的股票。他们对该股票设定了 “行业表现优于大盘” 的评级和 280.00 美元的目标价格。汇丰全球研究在 10 月 1 日的研究报告中将 AbbVie 的评级从 “强力买入” 下调至 “持有”。派珀桑德勒在 11 月 5 日的研究报告中重申了 “增持” 评级，并将 AbbVie 的目标价格设定为 289.00 美元（上调自 284.00 美元）。最后，美国银行在 10 月 3 日的报告中将 AbbVie 的目标价格从 220.00 美元上调至 251.00 美元，并给予该公司 “中性” 评级。两位投资分析师对该股票给予 “强力买入” 评级，十三位给予 “买入” 评级，十位给予 “持有” 评级。根据 MarketBeat 的数据，AbbVie 的平均评级为 “适度买入”，共识目标价格为 241.85 美元。</p>
</div><ul>
<li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健轮动正在进行中：3 只领先股票</li>
</ul>
</div><p><strong>View Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ABBV 股票报告</strong></p>
</div><h2>AbbVie Trading Down 1.8%</h2>
<div class="lb-trans"><h2>AbbVie 股价下跌 1.8%</h2>
</div><p>Shares of NYSE:ABBV opened at $227.57 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $402.20 billion, a P/E ratio of 108.37, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The firm has a fifty day moving average of $227.62 and a two-hundred day moving average of $206.42.</p>
<div class="lb-trans"><p>纽约证券交易所代码：ABBV 的股票在周五以 227.57 美元开盘。AbbVie Inc.的 12 个月低点为 164.39 美元，12 个月高点为 244.81 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务与股本比率为 44.14。该公司的市值为 4022 亿美元，市盈率为 108.37，市盈增长比率为 1.42，贝塔值为 0.50。该公司的 50 日移动平均线为 227.62 美元，200 日移动平均线为 206.42 美元。</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底线</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to analysts' expectations of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The business's revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>AbbVie（纽约证券交易所代码：ABBV - 获取免费报告）最近在 10 月 31 日发布了季度盈利数据。该公司报告每股收益（EPS）为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。AbbVie 的股本回报率为 699.66%，净利润率为 6.45%。该公司在本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。去年同期，该公司的每股收益为 3.00 美元。该公司的季度收入同比增长 9.1%。AbbVie 已将其 2025 年第四季度的指导目标设定为 3.320-3.360 EPS。平均而言，股票分析师预计 AbbVie Inc.在当前财年将发布 12.31 EPS。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>AbbVie 增加股息</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie's payout ratio is 524.24%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）登记的投资者将获得每股 1.73 美元的股息。该股息的除息日期为 1 月 16 日（星期五）。这比 AbbVie 之前的季度股息 1.64 美元有所增加。这代表着每年 6.92 美元的股息，收益率为 3.0%。AbbVie 的派息比率为 524.24%。</p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于 AbbVie</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc.在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道 Behçet 病以及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块状银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Basic Materials Stocks Investing</li>
<li>3 Stocks to Buy for the Evolution of AI Infrastructure</li>
<li>Investing in Construction Stocks</li>
<li>How Semtech’s Data Center Chips Are Powering the AI Boom</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Keysight Technologies' Surge: The Market Wakes Up to This AI Play</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 AbbVie</li>
<li>基础材料股票投资</li>
<li>3 只适合投资 AI 基础设施演变的股票</li>
<li>投资建筑股票</li>
<li>Semtech 的数据中心芯片如何推动 AI 热潮</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Keysight Technologies 的激增：市场意识到这一 AI 投资机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Neuberger Berman Group LLC 减少了对艾伯维公司 $ABBV 的持股